✦ LIBER ✦

A Risk-Benefit Assessment of Drugs Used for Neonatal Chronic Lung Disease

✍ Scribed by David G. Sweet, Professor Henry L. Halliday

Book ID: 119925163
Publisher: Springer International Publishing AG
Year: 2000
Tongue: English
Weight: 201 KB
Volume: 22
Category: Article
ISSN: 0114-5916
DOI: 10.2165/00002018-200022050-00006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Importance of benefit-to-risk assessment

Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS

✍ Gordon S. Francis 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 216 KB

Multivariate assessment of traditional r

Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates

✍ Mari Palta; Debra Gabbert; Marie R. Weinstein; Mary Ellen Peters; Newborn Lung P 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 721 KB

A Decision-Analysis Tool for Benefit-Ris

A Decision-Analysis Tool for Benefit-Risk Assessment of Nonprescription Drugs

✍ Brass, Eric P.; Lofstedt, Ragnar; Renn, Ortwin 📂 Article 📅 2013 🏛 Sage Publications 🌐 English ⚖ 163 KB

Benefit-Risk Assessment of Transdermal F

Benefit-Risk Assessment of Transdermal Fentanyl for the Treatment of Chronic Pain

✍ Dr Craig A. Kornick, Juan Santiago-Palma, Natalia Moryl, Richard Payne, Eugenie 📂 Article 📅 2003 🏛 Springer International Publishing AG 🌐 English ⚖ 196 KB

A Review of Quantitative Risk–Benefit Me

A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group

✍ Jeff J. Guo; Swapnil Pandey; John Doyle; Boyang Bian; Yvonne Lis; Dennis W. Rais 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB

A Preliminary Benefit-Risk Assessment of

A Preliminary Benefit-Risk Assessment of Lamivudine for the Treatment of Chronic Hepatitis B Virus Infection

✍ Dr Fabien Zoulim 📂 Article 📅 2002 🏛 Springer International Publishing AG 🌐 English ⚖ 180 KB